GlobeNewswire

Duo Security Launches UK Managed Service Provider and Security Solution Provider Programme

Dela

UK partner programme begins amid quadruple EMEA customer growth in past two years

LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Duo Security, one of the world's fastest growing cybersecurity providers, today announced the launch of its Managed Service Provider (MSP) and invitation-only Security Solution Provider programme in the United Kingdom. Duo's formal partner programme, which launched in the U.S. earlier this year, expands to the UK as the company has quadrupled its overall EMEA customer count from 450 to nearly 1,900 in the past two years.

Duo helps defend organizations against breaches by making security easy and effective. Anchored by its flagship two-factor authentication (2FA) app, Duo's cloud-based "Trusted Access" product offering verifies the identity of users and the health of their devices before granting them access to data and applications - helping prevent breaches and account takeover.

Unlike traditional security vendor programmes with tiered levels, Duo now offers a bespoke programme and enablement plans for security-centric UK-based solution providers invited to join the programme. The company expects more than half of its UK-based business to come through security solution provider and MSP partners as the programme progresses.

"Duo removes the pricing and implementation complexity of traditional partner models, allowing partners to be more profitable while providing their customers what they need to protect their data," said Matt Smith, Vice President of Worldwide Channels & Business Development. "Our comprehensive offering combined with our partner's expertise provides organizations a complete trusted access solution to protect their users, devices and applications without the typical complexity of most security products."

Duo's UK security solution provider business is led by EMEA Partner Manager Fiona Doak, a recent Duo hire with more than 26 years of experience in cybersecurity and technology. Doak previously held positions at RSA, Juniper Network, F5 Networks and WhiteHat Security.

"Duo brings a targeted, hyper-tailored approach to meeting the specific needs of partners and their customers," said Doak. "Each of the security partners we select has a strong practice with dedicated security architects and consultants, meaning the service they provide their customers is among the best in the industry."

Duo's UK Security Solution Provider programme already boasts partners such as Teneo, Saepio and Infosec Partners, and continues to expand with a select group of security-centric solution providers.

"It's so important today that security processes can be easily adopted and viewed by employees as business enablers, rather than a drag on productivity," said Marc Sollars, Chief Technology Officer at Teneo. "Our partnership with Duo means our customers can embed security much deeper into their company culture, because Duo's technology is such a pleasure to use. At Teneo, we've innovated around Duo's leading authentication technology to deliver a quick-to-implement and easy-to-use solution 'as a Service,' making security even simpler and intuitive for IT teams and employees. I deployed Duo in minutes via my own smartphone and was so amazed by how simple and effective it was, we immediately rolled it out across our own organization."

"The world's leading enterprises trust us to provide them sound advice and product recommendations, which is why we make sure each of our partners is of the highest caliber," said Andrew Pitt, Director at Saepio. "Duo's stellar reputation and proven track record of securing customers with an easy to use and effective product make it one of our hallmark product offerings for clients."

For more information, please visit https://duo.com/partners.

About Duo Security

Duo helps defend organizations against breaches through its easy and effective cloud-based Trusted Access product suite. The company verifies the identity of users and the health of their devices before granting them access to applications. Duo's intentional balance of security and usability has led the company to be a trusted partner to thousands of customers worldwide, including Dresser-Rand, Etsy, Facebook, K-Swiss, Random House, Yelp, Zillow, Paramount Pictures, and more. The Ann Arbor, Michigan-based company maintains offices in Austin, Texas; San Mateo, California; and London. Visit duo.com to find out more.

Media Contact
Meredith Corley & Jordan Fylonenko
Duo Security 
Press@duo.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Duo Security via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum